+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The ability of rodent islet amyloid polypeptide to inhibit amyloid formation by human islet amyloid polypeptide has important implications for the mechanism of amyloid formation and the design of inhibitors



The ability of rodent islet amyloid polypeptide to inhibit amyloid formation by human islet amyloid polypeptide has important implications for the mechanism of amyloid formation and the design of inhibitors



Biochemistry 49(5): 872-881



Islet amyloid polypeptide (IAPP) is a 37-residue polypeptide hormone that is responsible for islet amyloid formation in type II diabetes. Human IAPP is extremely amyloidogenic, while rat IAPP and mouse IAPP do not form amyloid in vitro or in vivo. Rat IAPP and mouse IAPP have identical primary sequences, but differ from the human polypeptide at six positions, five of which are localized between residues 20 and 29. The ability of rat IAPP to inhibit amyloid formation by human IAPP was tested, and the rat peptide was found to be an effective inhibitor. Thioflavin-T fluorescence-monitored kinetic experiments, transmission electron microscopy, and circular dichroism showed that rat IAPP lengthened the lag phase for amyloid formation by human IAPP, slowed the growth rate, reduced the amount of amyloid fibrils produced in a dose-dependent manner, and altered the morphology of the fibrils. The inhibition of human IAPP amyloid formation by rat IAPP can be rationalized by a model that postulates formation of an early helical intermediate during amyloid formation where the helical region is localized to the N-terminal region of IAPP. The model predicts that proline mutations in the putative helical region should lead to ineffective inhibitors as should mutations that alter the peptide-peptide interaction interface. We confirmed this by testing the ability of A13P and F15D point mutants of rat IAPP to inhibit amyloid formation by human IAPP. Both these mutants were noticeably less effective inhibitors than wild-type rat IAPP. The implications for inhibitor design are discussed.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056229853

Download citation: RISBibTeXText

PMID: 20028124

DOI: 10.1021/bi901751b


Related references

Amyloid formation by pro-islet amyloid polypeptide processing intermediates: examination of the role of protein heparan sulfate interactions and implications for islet amyloid formation in type 2 diabetes. Biochemistry 46(43): 12091-9, 2007

Analysis of the ability of pramlintide to inhibit amyloid formation by human islet amyloid polypeptide reveals a balance between optimal recognition and reduced amyloidogenicity. Biochemistry 54(44): 6704-6711, 2015

The ability of insulin to inhibit the formation of amyloid by pro-islet amyloid polypeptide processing intermediates is significantly reduced in the presence of sulfated glycosaminoglycans. Biochemistry 53(16): 2605-2614, 2014

The sulfated triphenyl methane derivative acid fuchsin is a potent inhibitor of amyloid formation by human islet amyloid polypeptide and protects against the toxic effects of amyloid formation. Journal of Molecular Biology 400(3): 555-566, 2010

Heparan Sulfate Proteoglycans Are Important for Islet Amyloid Formation and Islet Amyloid Polypeptide-induced Apoptosis. Journal of Biological Chemistry 290(24): 15121-15132, 2015

Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide. Implications for islet amyloid formation. Journal of Biological Chemistry 276(20): 16611-6, 2001

Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Letters 507(2): 200-204, 26 October, 2001

Characterization of the heparin binding site in the N-terminus of human pro-islet amyloid polypeptide: implications for amyloid formation. Biochemistry 45(30): 9228-9237, 2006

Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice. American Journal of Physiology. Endocrinology and Metabolism 289(4): E703-E709, 2005

Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proceedings of the National Academy of Sciences of the United States of America 93(8): 3492-3496, 1996

Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice (vol 289, pg 706, 2005). American Journal of Physiology Endocrinology and Metabolism 290(1): E205, 2006

Formation of islet amyloid in pancreatic islets from transgenic mice expressing human islet amyloid polypeptide. Clinical Science 87(1): 39P, 1994

Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin-T interactions: implications for mechanistic studies of beta-cell death. Biochemistry 47(22): 6016-6024, 2008

Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin. European Journal of Endocrinology 132(4): 487-496, 1995

Oophorectomy promotes islet amyloid formation in human islet amyloid polypeptide transgenic mice. Diabetes 50(Suppl. 1): S184-S185, 2001